TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26927501

Group type: EXPERIMENTAL
Intervention: NA (5 mg/d) with CEE (0.625 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: NA (5 mg/d) with placebo
Number of subjects: 50
Study: 26291768

Group type: EXPERIMENTAL
Intervention: Docetaxel with PANVAC (arm A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Docetaxel alone (arm B)
Number of subjects: 48
Study: 23870813

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 610

Group type: COMPARATOR
Intervention: Discontinuous treatment
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 610

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 610
Study: 21757823

Group type: EXPERIMENTAL
Intervention: hANP group (100 μg bolus injection of hANP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo group (physiological saline injection)
Number of subjects: 67
Study: 19242495

Group type: EXPERIMENTAL
Intervention: Cladribine (9 mg/m² per dose) and cytarabine (500 mg/m² per day) - arm B
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cladribine (9 mg/m² per dose) and cytarabine (500 mg/m² per dose) - arm A
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 96
Study: 16531618

Group type: COMPARATOR
Intervention: Vascular brachytherapy (VBT) with a beta source (n = 201)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent implantation (n = 195)
Number of subjects: 396
Study: 15144480

Group type: EXPERIMENTAL
Intervention: Elaborative pre‐talk
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Elaborative during-talk
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Elaborative post-talk
Number of subjects: 128

Group type: COMPARATOR
Intervention: Empty talk (during the event)
Number of subjects: 128
Study: 10895406

Group type: EXPERIMENTAL
Intervention: Men and women of all ages presenting with acute coronary disease
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Older persons with AMI
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Men with AMI
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Elderly patients with unstable angina
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Women with unstable angina
Number of subjects: 1782
Study: 9354205

Group type: EXPERIMENTAL
Intervention: ACT-10 (amoxycillin 1000 mg b.d. + clarithromycin 500 mg b.d. + omeprazole 20 mg daily for 10 days)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Dual therapy (clarithromycin 500 mg t.d.s. + omeprazole 40 mg daily for 14 days)
Number of subjects: 267
Study: 8225301

Group type: EXPERIMENTAL
Intervention: Psychoeducational inpatient family intervention
Number of subjects: 169

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 169
Study: 3161825

Group type: EXPERIMENTAL
Intervention: 100 micrograms of alpha‐human atrial natriuretic peptide injected intravenously
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison with normotensive volunteers
Number of subjects: 6
Study: 31927128

Group type: EXPERIMENTAL
Intervention: SC-model (structural connectome)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Tract-model (atlas-based tract)
Number of subjects: 82

Group type: COMPARATOR
Intervention: CV-model (clinical variables model)
Number of subjects: 82
Study: 29179027

Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smoking cessation
Number of subjects: 0
Study: 26241686

Group type: EXPERIMENTAL
Intervention: Atomized intraperitoneal ropivacaine (AIR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Atomized intraperitoneal saline (AIS)
Number of subjects: 55
Study: 26225661

Group type: COMPARATOR
Intervention: D1 gastrectomy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Overall postoperative morbidity
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Disease free survival
Number of subjects: 131
Study: 23385553

Group type: EXPERIMENTAL
Intervention: Vitamin D2 40,000 IU per week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vitamin D2 20,000 IU per week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 20363510

Group type: EXPERIMENTAL
Intervention: Oseltamivir (2mg/kg) given twice daily for 5 days
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Oseltamivir (2mg/kg)
Number of subjects: 452
Study: 17554248

Group type: EXPERIMENTAL
Intervention: Green tea-extract powder supplementation (544 mg polyphenols, 456 mg catechins daily for 2 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no intervention for the first 2 months)
Number of subjects: 60
Study: 16600720

Group type: EXPERIMENTAL
Intervention: Repeat transurethral resection (ReTUR) plus intravesical mitomycin C (MMC)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Initial transurethral resection (TURB) plus intravesical MMC
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Repeat transurethral resection (ReTUR) plus intravesical MMC
Number of subjects: 142
Study: 12762258

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 14986739

Group type: EXPERIMENTAL
Intervention: Becaplermin (recombinant human platelet-derived growth factor BB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DFS-SF (Diabetic Foot Ulcer Scale-Short Form)
Number of subjects: 0
Study: 10470338

Group type: EXPERIMENTAL
Intervention: Presence of the allelic family MAD20 of MSP1 at day 0
Number of subjects: 81
Study: 8599310

Group type: EXPERIMENTAL
Intervention: Reported energy intake from food records (6.98+/‐1.58 MJ/d)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Energy expenditure measured by the doubly labeled water method (9.00+/‐2.08 MJ/d)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Correlation between reported energy intake and expenditure
Number of subjects: 29
Study: 1958394

Group type: EXPERIMENTAL
Intervention: Cinnarizine 3 x 75 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: No Cinnarizine (Control)
Number of subjects: 17
Study: 6412638

Group type: EXPERIMENTAL
Intervention: 20 mg capsule of powdered sodium cromoglycate delivered by turbo inhaler (spinhaler)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1 mg of aerosolised sodium cromoglycate delivered by pressurised cannister inhaler (aerosol)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31383853

Group type: EXPERIMENTAL
Intervention: Psychopharmacological and psychotherapeutic treatment in MARS study
Number of subjects: 1826

Group type: EXPERIMENTAL
Intervention: Clustering of MARS discovery sample
Number of subjects: 1826

Group type: EXPERIMENTAL
Intervention: Prediction patterns based on clinical baseline items
Number of subjects: 1826

Group type: EXPERIMENTAL
Intervention: Model-based clustering
Number of subjects: 1826
Study: 28626220

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 500 μg subcutaneously every 3 weeks for 24 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa during the 48-week open-label period
Number of subjects: 147
Study: 27433865

Group type: EXPERIMENTAL
Intervention: Dance therapy (3 sessions weekly for 2 months)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Self-care treatment advice (control group)
Number of subjects: 52
Study: 24210745

Group type: EXPERIMENTAL
Intervention: Action-shooter game
Number of subjects: 81

Group type: COMPARATOR
Intervention: Racing game
Number of subjects: 81
Study: 21943317

Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 18
Study: 19158002

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol colonoscopy-like preparation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Traditional liquid diet
Number of subjects: 116
Study: 18251251

Group type: EXPERIMENTAL
Intervention: Commercial kit based on primer extension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subsequent sequencing analysis
Number of subjects: 0
Study: 15971459

Group type: EXPERIMENTAL
Intervention: Early invasive management
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 166
Study: 11990913

Group type: EXPERIMENTAL
Intervention: Dexanabinol (48 or 150 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (1 or 3 mL vehicle)
Number of subjects: 67
Study: 9641187

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 4 IU/m2/day for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 8120654

Group type: COMPARATOR
Intervention: Low fiber diet (15 g total dietary fiber/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diet supplemented with 62 g/d of brewer's spent grain
Number of subjects: 10
Study: 2929483

Group type: EXPERIMENTAL
Intervention: Isolated soy-protein-based formula with added carnitine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isolated soy-protein-based formula without added carnitine (control)
Number of subjects: 0
Study: 947448

Group type: EXPERIMENTAL
Intervention: Specially designed stretcher suspension system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purpose-built ambulance
Number of subjects: 0
Study: 31919523

Group type: EXPERIMENTAL
Intervention: Higher-magnitude contingency management (CM-H)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Low-magnitude contingency management (CM-L)
Number of subjects: 161
Study: 29944915

Group type: EXPERIMENTAL
Intervention: Gaming group (3D first-person shooter)
Number of subjects: 29
Study: 27121777

Group type: EXPERIMENTAL
Intervention: Baseline RA scores and follow-up assessments
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Baseline erosions, female gender, better mental health, lower DAS28-P
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Baseline OST scores
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Baseline hand OA
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Inflammatory disease activity
Number of subjects: 512
Study: 25687900

Group type: EXPERIMENTAL
Intervention: Men's Safer Sex (MenSS) website
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual sexual health clinical care
Number of subjects: 166
Study: 23945447

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (30 mg/d, 50 mg/d, or 70 mg/d)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 20102786

Group type: EXPERIMENTAL
Intervention: Scopolamine (cholinergic antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological-induced menopause (GnRHa treatment)
Number of subjects: 0
Study: 18069117

Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both PVP and OP
Number of subjects: 125
Study: 16504462

Group type: EXPERIMENTAL
Intervention: Spider phobics
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonphobics
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Spider phobics and nonphobics
Number of subjects: 50
Study: 12941030

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Oral anticoagulants (OA)
Number of subjects: 1379
Study: 11524494

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 9301385

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia
Number of subjects: 31

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 31
Study: 8300811

Group type: EXPERIMENTAL
Intervention: Growth hormone 12 IU/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3570862

Group type: EXPERIMENTAL
Intervention: 650 micrograms daily vitamin A supplement
Number of subjects: 0
Study: 2568777

Group type: EXPERIMENTAL
Intervention: 0.75 ml iopromide/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 ml iopromide/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 ml iopromide/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.0 ml iopromide/kg body weight
Number of subjects: 0
Study: 31430058

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) for 1 year
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for 2 years
Number of subjects: 97
Study: 31742796

Group type: EXPERIMENTAL
Intervention: Interactive program (CBT-based, telepsychology-delivered)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Active control (psychoeducational website)
Number of subjects: 46
Study: 28265880

Group type: EXPERIMENTAL
Intervention: Intravenous morphine administration
Number of subjects: 0
Study: 25043482

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Health promotion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Participation‐centered course
Number of subjects: 44
Study: 23833309

Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2))
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: High-dose IFN-α2b (HDI)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Observation (surgery alone)
Number of subjects: 189
Study: 21824454

Group type: EXPERIMENTAL
Intervention: lisdexamfetamine
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: triple‐bead mixed amphetamine salts (MAS)
Number of subjects: 831

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 831
Study: 19853815

Group type: EXPERIMENTAL
Intervention: Aromatherapy intervention of lavender and ginger essential oils
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo intervention of jojoba oil
Number of subjects: 94
Study: 16755435

Group type: EXPERIMENTAL
Intervention: MBO model of treatment (experimental group U[+])
Number of subjects: 494

Group type: COMPARATOR
Intervention: Conventional medical treatment (control group K[+])
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: MBO(+) patients
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Both experimental groups (U[+], U[−])
Number of subjects: 494
Study: 12692663

Group type: EXPERIMENTAL
Intervention: Intervention group (self-transcendence support group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison group (non-participants)
Number of subjects: 39
Study: 10474470

Group type: EXPERIMENTAL
Intervention: Topical 60% DMSO applied before each filling session
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional tissue expansion
Number of subjects: 40
Study: 8627841

Group type: EXPERIMENTAL
Intervention: High ligation of the internal spermatic vein
Number of subjects: 85

Group type: COMPARATOR
Intervention: Followed without any treatment
Number of subjects: 85
Study: 1763406

Group type: EXPERIMENTAL
Intervention: Group A (7.5 Gy point A dose)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Group B (6 Gy point A dose)
Number of subjects: 138
Study: 6283076

Group type: EXPERIMENTAL
Intervention: Gold therapy
Number of subjects: 0
Study: 31380605

Group type: EXPERIMENTAL
Intervention: Standard hemodialysis (HD) with a polysulfone membrane
Number of subjects: 155

Group type: COMPARATOR
Intervention: Predilution hemodiafiltration (HDF) with the same polysulfone membrane
Number of subjects: 155
Study: 28394361

Group type: EXPERIMENTAL
Intervention: Walnut oil (15 cc daily for 90 days)
Number of subjects: 100
Study: 26559870

Group type: EXPERIMENTAL
Intervention: Students with ptosis
Number of subjects: 4106

Group type: COMPARATOR
Intervention: Students without ptosis
Number of subjects: 4106

Group type: EXPERIMENTAL
Intervention: Students with bilateral ptosis
Number of subjects: 4106

Group type: EXPERIMENTAL
Intervention: Ptotic eyes
Number of subjects: 4106

Group type: COMPARATOR
Intervention: Non-ptotic eyes
Number of subjects: 4106
Study: 23417731

Group type: EXPERIMENTAL
Intervention: Collaborative QI intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Existing communication structure
Number of subjects: 12
Study: 21704493

Group type: EXPERIMENTAL
Intervention: Caffeine (480 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham (24 mg)
Number of subjects: 16
Study: 19222109

Group type: EXPERIMENTAL
Intervention: DG + KH group
Number of subjects: 151

Group type: COMPARATOR
Intervention: MT group
Number of subjects: 151

Group type: COMPARATOR
Intervention: DG group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: MT + KH group
Number of subjects: 151
Study: 16547328

Group type: EXPERIMENTAL
Intervention: Topical ciclosporin A 0.05%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14723265

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antiepileptic agents (phenytoin, phenobarbital, carbamazepine, valproic acid)
Number of subjects: 0
Study: 11232180

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy for severe acute alcoholic hepatitis
Number of subjects: 0
Study: 8694204

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 81

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Halothane
Number of subjects: 81
Study: 1597912

Group type: EXPERIMENTAL
Intervention: Betacarotene as a possible skin cancer preventive agent
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Heavy smokers
Number of subjects: 1805
Study: 6689670

Group type: EXPERIMENTAL
Intervention: Amino acid mixture (L‐phenylalanine, L‐tryptophan) infused intraduodenally at increasing rates (0.2, 0.8, and 3.2 ml X min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Normal saline infused into the intestine at increasing rates (0.2, 0.8, and 3.2 ml X min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mannitol solutions of increasing osmolality (370, 520, and 700 mosmol X kg‐1) infused into the duodenum at 0.2 ml X min‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Atropine infusion (20 micrograms X kg‐1 X h‐1)
Number of subjects: 8
Study: 31483549

Group type: EXPERIMENTAL
Intervention: Proactive outreach intervention (mailed invitation and telephone calls, free cessation treatment including nicotine replacement therapy and intensive telephone counseling)
Number of subjects: 2406

Group type: COMPARATOR
Intervention: Usual care (access to a primary care physician, insurance coverage of FDA-approved smoking cessation medications, and the state's telephone quitline)
Number of subjects: 2406

Group type: EXPERIMENTAL
Intervention: Proactive outreach intervention
Number of subjects: 2406
Study: 30004139

Group type: EXPERIMENTAL
Intervention: MOUTh (Managing Oral Hygiene Using Threat Reduction)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 27770740

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 25414155

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg single dose, titrated to 1.8 mg after 21 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23080427

Group type: EXPERIMENTAL
Intervention: ProDisc-C
Number of subjects: 209

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 209
Study: 20206556

Group type: EXPERIMENTAL
Intervention: 1% polidocanol foam
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 3% polidocanol foam
Number of subjects: 143
Study: 16446126

Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) at 5hPa
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no NEP)
Number of subjects: 8
Study: 12899648

Group type: EXPERIMENTAL
Intervention: PolyHeme
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 11187059

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 9424967

Group type: COMPARATOR
Intervention: Psychological treatment (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg orally (Group II)
Number of subjects: 40
Study: 8462805

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (4 g per day intravenously for 7 days)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 3517742

Group type: EXPERIMENTAL
Intervention: PhEA 34c (1.9% sodium hyaluronate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 15
Study: 30238574

Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide at a dose of 500 mg once daily
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 26504153

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg) plus prednisone (5 mg)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg) plus exemestane (25 mg)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Exemestane (25 mg)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus exemestane (AAE)
Number of subjects: 297
Study: 26098476

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (1.2 g EPA/DHA/day), n=85
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (olive oil), n=41
Number of subjects: 126
Study: 22808955

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 731
Study: 20523080

Group type: EXPERIMENTAL
Intervention: High-frequency left (HFL) rTMS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Low-frequency right (LFR) rTMS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Whole sample
Number of subjects: 74
Study: 18270575

Group type: EXPERIMENTAL
Intervention: HAMS‐ORS (hypo‐osmolar ORS with amylase resistant high amylose maize starch 50g/L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: HO‐ORS (hypo‐osmolar ORS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HAMS‐ORS
Number of subjects: 50

Group type: COMPARATOR
Intervention: HO‐ORS
Number of subjects: 50